Randomized, Double-Blind, Phase III LEAP-003 Study of First-Line Lenvatinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab for Unresectable or Metastatic Melanoma
{{output}}
Background: Lenvatinib plus pembrolizumab demonstrated antitumor activity in advanced melanoma after prior anti-PD-(L)1 therapy in LEAP-004. Here, we report results from LEAP-003 (NCT03820986) which evaluated first-line lenvatini... ...
